Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants

Hongjie Chen; Jiepeng Chen; Fuping Zhang; Yuanhui Li; Ronghua Wang; Qiang Zheng; Xu Zhang; Jun Zeng; Feng Xu; Yiguang Lin

doi:10.3389/fcvm.2022.1076420

Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants

Front Cardiovasc Med. 2022 Dec 5:9:1076420. doi: 10.3389/fcvm.2022.1076420. eCollection 2022.

Authors

Hongjie Chen¹, Jiepeng Chen², Fuping Zhang³, Yuanhui Li⁴, Ronghua Wang², Qiang Zheng², Xu Zhang², Jun Zeng², Feng Xu⁵, Yiguang Lin^{1

6

7}

Affiliations

¹ Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
² Sungen Bioscience Co. Ltd., Shantou, China.
³ Department of Pharmacy, Shenyang Red Cross Hospital, Shenyang, China.
⁴ Guangzhou Center, Sinopharm Group Pharmaceutical Co., Ltd., Guangzhou, China.
⁵ Antithrombotic & Thrombolytic Innovative Drug Research Center, Shenyang Pharmaceutical University, Shenyang, China.
⁶ The Central Laboratory, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
⁷ School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia.

Abstract

[This corrects the article DOI: 10.3389/fcvm.2022.964977.].

Keywords: Nattokinase (NK); anti-atherogenic drug; atherosclerosis; hyperlipidaemia; lipid lowering agent; lipid lowering effect; nattokinase; retrospective study.

Publication types

Published Erratum